Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. This novel cardiac tool leverages the power of high-speed MR imaging to help physicians detect and measure the effects of cardiotoxicity during cancer treatments. Physicians are using MyoStrain as a critical solution to holistically evaluate and protect patient heart health without interfering with oncology care. Today, with mounting evidence that many oncology treatments cause cardiotoxicity, new cancer patients and survivors are at an increased risk of cardiovascular disease. Unfortunately, diagnostics often cannot detect cardiotoxicity until symptoms occur, which is usually a sign of cardiac damage. The MyoStrain test works by quantifying segmental strain across 48 segments of the heart. This safe and rapid test produces a comprehensive report and MyoHealth™ Score, a single number that helps indicate patient heart health and enables physicians to manage cardio-protection over time. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.